GHRP-2 vs Ipamorelin

Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.

GHRP-2 (growth hormone-releasing peptide-2; pralmorelin; KP-102) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist developed as a GH secretagogue with established efficacy in stimulating pulsatile GH release from pituitary somatotrophs, characterized by potent GH stimulation alongside non-selective co-stimulation of cortisol and prolactin secretion. As a first-generation GHRP, GHRP-2 achieves its GH-secretory effect through direct GHS-R1a agonism with amplification by endogenous GHRH; it is distinguished from later selective GHRPs such as ipamorelin by its non-selective endocrine profile, and synergistic GH stimulation is observed when combined with GHRH analogs in diagnostic protocols. GHRP-2 has been validated as a diagnostic agent for the GHRP-2 stimulation test used in Japan to assess GH secretion capacity in adults with suspected hypopituitarism or post-surgical pituitary dysfunction, with published human clinical data supporting its reliability as a GH stimulation tool in endocrine diagnostic practice. GHRP-2 has no FDA approval for any therapeutic or diagnostic indication in the United States; it is used diagnostically in Japan and as a research compound elsewhere, with no approved indication for GH enhancement, performance, or anti-aging applications, and its non-selective endocrine stimulation profile represents a relevant consideration versus more selective GH secretagogues. GHRP-2 dosage in research contexts: doses of 100–300 mcg per subcutaneous injection are documented across research protocols, typically administered 2–3 times daily. Co-administration with a GHRH analog (such as CJC-1295 or sermorelin) produces synergistic GH release and is studied in combination protocols for this reason. Administration is by subcutaneous injection following reconstitution with bacteriostatic water. GHRP-2 vs GHRP-6 vs ipamorelin: GHRP-2 produces potent GH release but with co-stimulation of cortisol and prolactin, similar to GHRP-6. The key distinguishing feature of GHRP-6 is stronger appetite stimulation (ghrelin-like effect); GHRP-2 produces less appetite stimulation with comparable or slightly greater GH output per dose. Both are non-selective compared to ipamorelin, which was developed specifically to achieve GH stimulation without the cortisol and prolactin co-elevation that characterizes first-generation GHRPs. For research contexts prioritizing GH selectivity, ipamorelin is generally preferred; GHRP-2 is used where its diagnostic validation and potent GH stimulation profile are the research objectives.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.